chrisvoncsefalvay/vaers-outcomes huggingface dataset:
last time I got the flu was when I got the flu shot; Initial information received on 19-Oct-2023 regarding an unsolicited valid Social Media non-serious case received from a consumer/non-hcp.  This case involves an unknown age and unknown gender patient who last time  got the flu was when he got the flu shot (Influenza vaccine).  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received a dose of suspect Influenza vaccine by unknown manufacturer (strength, dose, formulation, frequency, lot number and expiry date: not reported) via unknown route in unknown administration site for prophylactic vaccination (Immunisation). Information on the batch number was requested  On an unknown date the patient last time got the flu was when he got the flu shot (influenza) (unknown latency).  Reporter Commented: Atleast they aren't hiding the fact that they're getting paid. The last time I got the flu was when I got the flu shot,  And I've worked in childcare with kids sneezing in my face for years. It's a no from me  Action taken: not applicable.  It was not reported if the patient received a corrective treatment for the event (last time I got the flu was when I got the flu shot).  At time of reporting, the outcome was Unknown for the event last time i got the flu was when i got the flu shot.
no additional AE's were reported.; a patient was administered VARIVAX intramuscularly instead of subcutaneously.; This spontaneous report was received from a other health professional and referred to a 14-year-old male patient. The patient's concomitant medications, pertinent medical history and drug reactions/allergies were not reported.  On 27-FEB-2023, the patient was vaccinated with varicella virus vaccine live (oka/merck) (VARIVAX) subcutaneous injection (0.5 milliliter, lot #W018824, expiration date: 14-JUN-2024, anatomical location and strength were not provided) intramuscularly instead of subcutaneously for prophylaxis (Incorrect route of product administration). No additional adverse events (AEs) were reported (No adverse event).
Rash around vaccination site. About 5 inches.  Itchy and a bit stiff.
In December began having abdominal pain, nausea, diarrhea, dehydration, weakness, extreme tiredness
swollen armpit lymph nodes and upper right arm; swollen armpit lymph nodes and upper right arm; arm tingling to fingers; very uncomfortable; Right armpit discomfort; This is a spontaneous report from a contactable healthcare professional (the patient). A 48-year-old non-pregnant female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, Lot number EL0140), intramuscular in the right arm on 20Jan2021 at 10:00 (at the age of 48-years-old) as a single dose for Covid-19 immunization. Medical history included central nervous system disorder (CIS) from an unknown date. The patient did not have any allergies to medications, food or other products. The patient previously received dose 1 of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, Lot number EL0140) on 30Dec2020 in the right arm. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient's concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 21Jan2021 at 18:00, the patient experienced right armpit discomfort. On 22Jan2021 the patient experienced swollen armpit lymph nodes and upper right arm leaving the right arm tingling to fingers and very uncomfortable. Therapeutic measures were not given for the events. The clinical outcome of the events axillary pain, lymphadenopathy, peripheral swelling, paresthesia and discomfort was not recovered. It was reported that since the vaccination (dose 1), the patient had been tested for COVID-19 via a PCR nasal swab on 19Jan2021 with a negative result.
Extreme fatigue; low grade fever; Headache; This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (Extreme fatigue), PYREXIA (low grade fever) and HEADACHE (Headache) in a 27-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Jan-2021, the patient experienced FATIGUE (Extreme fatigue), PYREXIA (low grade fever) and HEADACHE (Headache). At the time of the report, FATIGUE (Extreme fatigue), PYREXIA (low grade fever) and HEADACHE (Headache) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported. Treatment medications were not provided by reporter.   Reporter did not allow further contact
4/19 throat swelling, SOB, went to personal MD cheeks red, eyelids swelled, shot of cortisone, dose of Benadryl. T-102, went to 103.
Woke up with a perfect C in hives...raised, red, itchy bumps...about 2' from injection site.   Treated with oral Benadryl and topical hydro-cortisone.  Notified my doctor, who spoke with an allergist and assured me it was ok. Duration...about 3 days of hives, the C remained pink for a few days more and I treated it with aloe gel.
The rash is on her face; Shingles; This case was reported by a other health professional via call center representative and described the occurrence of shingles in a 63-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 1st October 2019, the patient received the 1st dose of Shingrix. On 4th November 2019, 34 days after receiving Shingrix, the patient experienced shingles. On an unknown date, the patient experienced rash. The patient was treated with valaciclovir hydrochloride (Valtrex). On an unknown date, the outcome of the shingles was unknown and the outcome of the rash was recovering/resolving.   It was unknown if the reporter considered the shingles and rash to be related to Shingrix.  Additional details were reported as follows: The patient received Shingrix and experienced shingles and rash on her face. The patient was treated with Valtrex and the rash has improved, but it was still ongoing at the time of reporting.  The reporter consented to follow up.
Very sore arm, enable to lift or move due to pain due to pneumonia shot in left arm.
I began experiencing fatigue, body aches, and extreme soreness that began when I woke up the next morning after receiving the vaccine that lasted about 30 hours. I did not run a fever I did previously have Covid-19 on 11/6/20.
I started to have a runny nose and itchy eyes. I then got a sore throat and Nasal Congestion. I took a home test for Covid-19 and it was Positive. I went to my doctor the next day and he Prescribed Monoclonal Antibodies and Azithromycin Z-PAC. I was sick with those symptoms for seven days and I isolated for ten days. I did a Rapid test and it was negative. I did not loose my sense of taste or smell. My symptoms seemed worse at night than during the day. My throat was very sore at night and better during the day.
Few hours after I was a little sore and fatigued. The next day may 22 was very sore very fatigued, chills, headache, mild nausea, immense pain at the injection site big red rash around the injection site hard mass around the injection site painful to the touch painful to move arm may 24th still red around the injection site, still swelled and hard mass under the injection site, still painful to the touch and it's hot to the touch and starting to itch at the injection site
headache; generalized muscle pain/myalgia; injection arm soreness; intermittent nausea; intermittent nausea; pyrexia/fever (99.2°-99.6°F); interference with daily activities due to AEs; This is a spontaneous report from a contactable consumer or other non-HCP (patient reported for self). A 46-year-old male patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot Number: EW0179), via an unspecified route of administration, administered in left arm on 30Apr2021 13:00 (at the age of 46-years-old) as dose 2, single for COVID-19 immunization. Facility type Vaccine mentioned as Other. The patient did not receive any other medication in two weeks. The patient did not had COVID prior vaccination. Other medication reported as none. The patient medical history was not reported.  No known allergies per reporter's knowledge. The patient's concomitant medications were not reported. Patient had earlier received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Lot Number: EW0162), via an unspecified route of administration, administered in left arm on 09Apr2021 13:30 (at the age of 45-years-old) as dose 1, single for COVID-19 immunization. On 01May2021 10:00, the patient experienced pyrexia/fever (99.2 degree-99.6 degree F), headache, generalized muscle pain/myalgia, injection arm soreness, and intermittent nausea. All adverse events were mild in severity except for headache which was moderate. No concomitant use of antipyretic or pain medication taken. No prescription or OTC medications taken. There was interference with daily activities due to AEs (Adverse Events). Symptoms peaked around 01May 3PM and fully resolved around 10PM. The patient underwent lab tests and procedures which included body temperature: 99.2 degree-99.6 degree fahrenheit on 01May2021. Since the vaccination, patient has not been tested for COVID-19. No treatment was given for the reported events. The outcome of all events was reported as recovered on 01May2021 at 22:00 PM; interference with daily activities due to AEs was unknown. Device Date : 03May2021.  No follow-up attempts are possible. No further information is expected.
shingles; Body aches; Congestion; Coughing; Stinging during vaccination; Sore arm; Rash on armpit/rash on back/rash on above right breast; Bruise on arm and injection site; cought the cold; throat virus; This case was reported by a consumer via call center representative and described the occurrence of shingles in a 66-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included pneumococcal vaccine (Pneumonia Shot) for cough.   On 25th June 2019, the patient received the 1st dose of Shingrix (intramuscular) .5 ml and Pneumonia Shot at an unknown dose and frequency. On an unknown date, 5 days after receiving Shingrix, the patient experienced shingles, general body pain, nasal congestion, cough, injection site stinging, pain in arm, rash, bruise, cold and throat infection. The patient was treated with antivirals nos. On an unknown date, the outcome of the shingles, cold and throat infection were unknown and the outcome of the general body pain, nasal congestion, cough, injection site stinging and pain in arm were recovered/resolved and the outcome of the rash and bruise were not recovered/not resolved.   It was unknown if the reporter considered the shingles, general body pain, nasal congestion, cough, injection site stinging, pain in arm, rash, bruise, cold and throat infection to be related to Shingrix.  Additional details were provided as follows: The patient received Shingrix vaccine and an unknown pneumonia vaccine at the same time. As the Shingrix vaccine was being administered it stung. Her arm had a bruise and became sore for five days. The soreness has resolved but there was still a light bruise at the injection site. Right after receiving the vaccine she experienced body aches and felt like she had a throat virus because she had congestion and coughing. She thought she had caught the cold that her both her husband and son had at the same time. It took five says for these symptoms to resolve. Five days after receiving the Shingrix vaccine she noticed one spot above her right breast. More spots developed and formed a line of this rash to under her right armpit. On her back there are two spots. These spots initially stung but did not at the time of reporting. She went to Urgent Care before the date of reporting and was given an antiviral medication. The nurse said she could, potentially, have shingles.  The reporter consented to follow up. The reporter gave permission for her physician to be contacted: Unable to obtain additional information.
dose on 5/19/21, and dose 6/2/22; This case was reported by a nurse via call center representative and described the occurrence of drug dose administration interval too short in a 12-year-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number MR5RK, expiry date 27th September 2023) for prophylaxis.   Previously administered products included Kinrix  (received a dose of Kinrix on 12th May 2014) and Boostrix  (received a dose of Boostrix on 19th May 2021).   On 2nd June 2022, the patient received Boostrix. On 2nd June 2022, unknown after receiving Boostrix, the patient experienced drug dose administration interval too short. On an unknown date, the outcome of the drug dose administration interval too short was unknown.   Additional Information: GSK receipt date: 02-Jun-2022 Reporter's comment: The registered nurse called to inquired that how to proceed or what to look for. The reporter reported that a Boostrix dose was administered on 19th May 2021 and then the patient was administered with a Boostrix dose on the day of reporting. The reporter did not consent to follow-up. Additional Supportive Information: The patient received a dose of Boostrix earlier than recommended interval, which led to shortening of vaccine schedule.
AT FIRST AREA OF INJECTION WAS HARD AND HOT LIKE IF I HAD A GOLF BALL SIZE LESION ON MY ARM VERY PAINFUL FEVER HEADACHE THAT HAPPENED AFTER EVERY SHOT I GOT (4) ANTHRAX VACCINATIONS ABOUT 8 MONTH IN THAT YEAR I GOT A RASH ON MY SCALP THAT AT THE TIME I ASSUMED IT WAS NOTHING BUT IT JUST STARTED TO GET WORSE AS TIME WENT BY AND A PUNCH BIOPSY WAS PERFORMED AND THE DERMATOLOGIST SAID IT IS PSORIASIS ALSO I HAVE BEAN DIAGNOSED WITH  ERYTHEMA NODOSUM THIS HAS ALL HAPPENED AFTER THE ANTHRAX VACCINATION 1ST DOSE 26MARCH03, 2 DOSE 09APR03, 3RD DOSE 24APR03, 4TH DOSE 29SEP03
This spontaneous report was received from a health care professional refers to an unspecified patients of unknown demographics. On an unknown date the patients were vaccinated with improperly stored doses of ZOSTAVAX (lot # L028280; expiry: 28-OCT-2016) (dose and route unspecified). No medical history, concurrent conditions or concomitant therapies were reported. Healthcare worker states that these unspecified vaccinations occurred between 30-DEC-2015 and 03-FEB-2016. Temperature: -11.8C. Time frame: 1903 minutes (or 31 hours, 43 minutes). There was a previous temperature excursion and the time frame was cumulative since 30-DEC-2015. The call was because of a data logger. No additional information provided. This is one of several reports received from the same reporter. Additional information has been requested.
HIB was ordered and given not PCV which the infant was due for. It was and ordering and an administration issue
PT wasn't feeling good and appeared pale white  after administration of the vaccine. pt fell unconsisious after 5 mins and emt was called. pt refused to go to hospital with them
I am experiencing a large (approx 4") hard swelling at the injection site and the center is approx 2" and very red.
Patient called and reported diarrhea, vomiting and nausea ~ 36 hours after vaccine was administered. Resolved in ~ 18 hours. Felt great the next day.
Low grade fever 99.1 degrees, increased blood pressure, hives, given antibiotics. All resolved in 48 hrs.
8 days after MMR, VZV, pt started tacticle temp x 24 hrs. Nex tday, broke out in morbilliform rash (small, raised blister bump with papule over scalp, face, thigh and torso). No other lesion subsequent.
Migraine every day for two weeks after the first dose and one week after the second dose. I have not had a period since before the first dose.
Realized after given to her, she was 17 and was not indicated by eua to receive this vaccine.  only Pfizer.
Raised feverish red area 3" X 2", about 2 inches below injection site. Fever on raised area went away after I took acetaminophen 2 - 500 mg tablets.  The red raised area is still present.  Please note that I had this same reaction  adverse reaction with the first shot as well (02/25/2021,  lot# 031LZ0A).
4/16/2022: On the 3d day from the second Moderna booster (4/7/2022), my 81 year old mother developed laryngitis.  She could barely talk.  She had no other symptoms.  She lives at an assisted living facility and it confirmed no fever or other side effects.  She's improved, but is not back to baseline.  I saw a write up on WHO website of the first report of similar side effects in a 28 year old, I think that's the age, patient.
Large baseball sized, painful, hard, reddened,  lump on arm day one decreased to golf ball size 4 days later. I had moderate chills progressed to severe chills, stomach pain,  and muscle/joint pain. Unable to work following day. I reported. It advised someone would be calling me. No one ever did. Chills, stomach and joint pain resolved. Still fatigued with painful lump on arm.
arm swelled & became red evening of day inject was given; seen @ clinic next day & was given oral ATB; responded well to tx;
had both Shingrix vaccine shots. I've had shingles outbreaks in the last year / Suspected vaccination failure; shingles outbreaks; pain and swelling in my left breast and arm pit; pain and swelling in my left breast and arm pit; pain and swelling in my left breast and arm pit; pain and swelling in my left breast and arm pit; This case was reported by a consumer and described the occurrence of suspected vaccination failure in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis and COVID-19 MRNA-1273 VACCINE (MODERNA (MRNA RIBONUCLEIC ACID VACCINE)) for prophylaxis.   Concomitant products included COVID-19 MRNA-1273 VACCINE (MODERNA (MRNA RIBONUCLEIC ACID VACCINE)).   On an unknown date, the patient received the 1st dose of Shingrix, the 2nd dose of Shingrix and the 2nd dose of MODERNA (MRNA RIBONUCLEIC ACID VACCINE). On an unknown date, unknown after receiving Shingrix and Shingrix, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles, breast swelling, breast pain, axillary pain and local swelling. The patient was treated with gabapentin. On an unknown date, the outcome of the vaccination failure and shingles were unknown and the outcome of the breast swelling, breast pain, axillary pain and local swelling were not recovered/not resolved.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingrix and Shingrix. It was unknown if the reporter considered the breast swelling, breast pain, axillary pain and local swelling to be related to Shingrix.  Additional details were reported as follows: This case was reported by patient himself/herself. The age group was not reported but was selected as an adult as per vaccine indication. The age at vaccination was not reported. The patient received both the Shingrix vaccines in the left arm. In 2020, the patient experienced shingles outbreaks. The patient received both Moderna vaccine shots in right arm. At the time of reporting, the patient had pain and swelling in left breast and arm pit. Mammograms and ultrasound performed and found no cancer. The patient saw a report from the CDC (Centers for Disease Control and Prevention) a day before reporting, regarding lymph node swelling in the breast and arm pit in reaction to the Covid vaccine in women who had the Covid virus and was recovered and the patient asked if it was possible that his/her pain and swelling was a reaction to Shingrix. The patient was currently taking Gabapentin for pain. The patient asked if there was anything he/she could do to relieve pain and swelling, and would it go away eventually or get worse. It was unknown if the reporter considered the breast swelling, breast pain, axillary pain and local swelling to be related to Moderna vaccine. This case was considered as suspected vaccination failure as details regarding time to onset and laboratory test confirming herpes zoster were unknown at the time of reporting.
Pt was vaccinated with Moderna when they should have received Pfizer. Vaccinator reports he chose the wrong syringe. Patient counseled and corrective action taken.
Covid-19 I tested positive for Covid-19 on December 26, 2022 I experienced tiredness, loss of appetite, fever, scratchy throat, bloody phlegm, I consumed cough meds and was prescribed PAXLOVID.
Patient developed full body, pruritic rash 4 days after vaccine given; no new soaps, detergents, food, medications
Pt came over with red/swollen inner upper left arm 9/14/13. (She received her Pneumovax on 9/12/13 on left deltoid and Fluzone HD on right deltoid.) I noticed a small white spot among the swollen area and informed her to go to urgent care.  Pt came back 1:50pm informing us that urgent care diagnosed her with staph infection possible due to not throughly clean the injection site.  Pt was given abx for it.
This case was reported by a pharmacist via call center representative and described the occurrence of injection site lump in a 81-year-old female patient who received SHINGRIX (batch number BF4J5, expiry date 5th July 2021) for prophylaxis. Concomitant products included SHINGRIX and Cortisone Topical Cream. On 2nd April 2019, the patient received the 2nd dose of SHINGRIX (intramuscular). On 3rd April 2019, 1 days after receiving SHINGRIX, the patient experienced injection site lump and injection site itching. On an unknown date, the outcome of the injection site lump and injection site itching were not recovered/not resolved. It was unknown if the reporter considered the injection site lump and injection site itching to be related to SHINGRIX. Additional details were provided as follows: The patient received 1st dose of SHINGRIX on 30th January 2019 with no issue. On 2nd day after vaccination, the patient developed bumps and itching around the site of the injection. The reporter told to the patient to put Cortisone cream on around the site of the injection.
Pt had 2 Varicella vaccinations 1) 9/12/01 2) 8/25/08 and pt got chicken pox 3/31/10.
pt recv vax NOV96 & exp an immed febrile rxn w/a temp of 105, fatigue & lethargy;lab eval revealed a positive test for mononucleosis;epstein Barre various was in latent phase according to lab eval performed in APR or MAY97;
Approximately 24 hours, post vax, a small erythematous papular eruption occurred on the legs and back, evolving over the next 24 hours into 4 bullae with 5mm diameter on the back of the lower legs bilaterally. Accompanied with fever but no other symptoms.
Tested COVID positive greater than 14 days after 2nd vaccine Narrative: Tested COVID positive >14 days post COVID vaccine
I'm not sure if we administered an expired vaccine to a patient in Nov; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (I'm not sure if we administered an expired vaccine to a patient in Nov) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 034C21A) for COVID-19 vaccination.     No Medical History information was reported.    In November 2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In November 2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (I'm not sure if we administered an expired vaccine to a patient in Nov). In November 2021, EXPIRED PRODUCT ADMINISTERED (I'm not sure if we administered an expired vaccine to a patient in Nov) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant and treatment medication details were reported.
Bruise at injection site. Some tingling in injection arm down to hand.  c/o tenderness in upper arm when grasping objects.  All of the sx gradually improved over a 8-10 days.